Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Pragnesh Patel

Interventional Cardiology Jefferson City, TN Medical Doctor

NPI 1568529006 CMS profile 116712

120 Hospital Dr Ste 260, Jefferson City, TN 37760

Open in the dashboard

General payments

$13,921

548 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$304,715 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Pragnesh Patel of Jefferson City, TN is reported in the CMS Open Payments database as having received $13,921 across 548 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $304,715 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 67th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $727 42
2024 General $1,789 73
2023 General $1,673 78
2022 General $3,980 96
2021 General $2,003 95
2020 General $1,581 75
2019 General $2,167 89

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Pragnesh Patel
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Pragnesh Patel were reported at $727. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Pragnesh Patel Interventional Cardiology median Middle half National median
2019 $2,167 $1,097 $329–$3,048 $163
2020 $1,581 $473 $161–$1,480 $114
2021 $2,003 $677 $233–$1,827 $132
2022 $3,980 $978 $333–$2,724 $149
2023 $1,673 $1,136 $382–$2,986 $160
2024 $1,789 $1,181 $395–$3,326 $164
2025 $727 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $2,847 10 payments
  2. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $1,734 65 payments
  3. Novartis Pharmaceuticals Corporation $1,619 110 payments
  4. Janssen Pharmaceuticals, Inc $1,220 76 payments
  5. AstraZeneca Pharmaceuticals LP $1,010 62 payments
  6. Cardiovascular Systems Inc. $757 29 payments
  7. Amgen Inc. $667 24 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $415 26 payments
  9. Sanofi-Aventis U.S. LLC $385 23 payments
  10. Boston Scientific Corporation $379 12 payments
  11. Other $2,889 111 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,823 534 payments
  2. Travel and Lodging $1,837 2 payments
  3. Education $260 12 payments
Products named General payments · program years 2019–2025
  1. Indigo System $2,476 6 payments
  2. LifeVest $1,734 65 payments
  3. XARELTO $1,269 78 payments
  4. ENTRESTO $797 60 payments
  5. FARXIGA $621 34 payments
  6. Repatha $602 20 payments
  7. LEQVIO $548 28 payments
  8. BRILINTA $385 28 payments
  9. AURYON LASER SYSTEM 100-120 VAC $369 4 payments
  10. Kerendia $322 21 payments
  11. Other $5,125 216 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

5,577

Median for Cardiology: 2,533

Drug cost

$1,340,000

Median for Cardiology: $485,213

Branded share of claims

45.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 326 $323,567
Xarelto Rivaroxaban Brand 337 $316,068
Entresto Sacubitril/Valsartan Brand 242 $285,572
Brilinta Ticagrelor Brand 211 $127,580
Farxiga Dapagliflozin Propanediol Brand 101 $94,177
Jardiance Empagliflozin Brand 43 $38,416
Repatha Sureclick Evolocumab Brand 45 $35,071
Multaq Dronedarone Hcl Brand 39 $30,324
Ranolazine Er Ranolazine Brand 116 $13,785
Vascepa Icosapent Ethyl Brand 24 $11,515

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 85 billing codes

Paid by Medicare

$471,390

Of which drugs: $2,421

Medicare patients

995

Average age 74

Services billed

6,404

534 women, 461 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 49%
Diabetes 41%
COPD 37%
Chronic kidney disease 36%
Atrial fibrillation 35%
Heart failure 31%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 109 436 $2,358

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ENTRESTO
  • Novartis Pharmaceuticals Corporation $128
$128 242 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $126
$126 — —
Repatha
  • Amgen Inc. $118
$118 45 —
XARELTO
  • Janssen Pharmaceuticals, Inc $113
$113 337 —
MULTAQ
  • SANOFI-AVENTIS U.S. LLC $99
$99 39 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

548 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record